Saturday, October 3, 2026
ExploreSearch
Via News
MarketFX

USD/CNH Is 1% Down In The Last 10 Sessions

USD/CNH Is 1% Down In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.02% for the last 10 sessions. At 04:06 EST on Monday, 8 April, USD/CNH (USDCNH) is $7.25.

USD/CNH's yearly highs and lows, it's 0.064% up from its 52-week low and 0.114% down from its 52-week high.

News about

  • Eur/usd weekly forecast: choppy trading routine as outlooks remain unclear - 07 April 2024. According to DailyForex on Sunday, 7 April, "The EUR/USD traded in a choppy manner all of last week and although it finished slightly higher than where it started, speculators who are bulls will not be resting easy.", "But trading results in the EUR/USD may be affected by these considerations in the days ahead and cause turbulence in the currency pair."
  • Eur/usd trades with modest losses amid stronger usd, holds above 1.0800 mark. According to FXStreet on Monday, 8 April, "This, along with the European Central Bank (ECB) meeting on Thursday, should provide some meaningful impetus to the EUR/USD pair.", "The EUR/USD pair struggles to capitalize on Friday's goodish rebound of around 50 pips from sub-1.0800 levels and meets with a fresh supply during the Asian session on Monday. "

More news about USD/CNH (USDCNH).

Categories

MarketFX

Tags

ForexForeign Exchange MarketCurrenciesUSDCNHUSD/CNHPrice DownFOREX Price DownForex Nowintelligent
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com